At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 512 enrolled
Drug / intervention
eryaspase +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
In Brief
A Phase 3 clinical trial evaluating eryaspase, Gemcitabine plus Abraxane, and 1 other intervention for Pancreatic Adenocarcinoma. Completed, enrolled 512 participants across 16 sites in 3 countries.
Detailed Summary
This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Adenocarcinoma
CountriesFrance, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartSep 2018
Primary CompletionAug 2021
Study CompletionJan 2022
TodayJul 2026
First PostedSep 11, 2018
Enrollment StartSep 15, 2018
Primary CompletionAug 30, 2021
Study CompletionJan 18, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 7.8 years ago
Interventions
eryaspasedrug
L-asparaginase encapsulated in erythrocytes (red blood cells)
Gemcitabine plus Abraxanedrug
gemcitabine, Abraxane
Irinotecan plus 5-FU plus leucovorindrug
irinotecan, 5-FU, leucovorin